Food and Drug Administration

Pulmonary-Allergy Drugs Advisory Committee

June 6,, 2005

Briefing Information

Chiron Corporation

NDA 50-799, Pulminiq (cyclosporine), inhalation solution, Chiron, proposed for the increase in survival and for the prevention of chronic rejection in patients receiving allogenic lung transplants, in combination with standard immunosuppressive therapy.

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Chiron Corporation Pulminiq (cyclosporine) Briefing Material

FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. 552). These redacted portions will appear as white space on the screen or on the printed page.

FDA Pulminiq (cyclosporine) Briefing Material

Bibliography
(Word) (PDF) (HTML)